Collegium Pharmaceutical, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period
Collegium Pharmaceutical, Inc. (COLL) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period of 174.79 thousand shares for the 12-month period ending 2020-12-31, per its 10-K filed 2021-02-25.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod · last filed 2021-02-25
- Collegium Pharmaceutical, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2019-12-31 was 85.87K shares.
- Collegium Pharmaceutical, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2019-09-30 was 172.56K shares, a 282.98% increase year-over-year.
- Collegium Pharmaceutical, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2019-06-30 was 155.01K shares, a 268.22% increase year-over-year.
- Collegium Pharmaceutical, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2019-03-31 was 111.13K shares, a 104.33% increase year-over-year.
- Collegium Pharmaceutical, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2020 was 174.79K shares, a 66.68% decline from fiscal 2019.
- Collegium Pharmaceutical, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2019 was 524.57K shares.
- Collegium Pharmaceutical, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2017 was 261.34K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 12 month as first filed |
|---|---|---|---|---|---|
| 2020-12-31 | 174.79K shares 10-K · filed 2021-02-25 | ||||
| 2019-12-31 | 85.87K shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | 258.43K shares derived: sum of 2 quarters · filed 2020-02-27 | 413.44K shares derived: sum of 3 quarters · filed 2020-02-27 | 524.57K shares 10-K · filed 2020-02-27 | |
| 2019-09-30 | 172.56K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | 327.57K shares derived: sum of 2 quarters · filed 2019-11-06 | 438.70K shares 10-Q · filed 2019-11-06 | ||
| 2019-06-30 | 155.01K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | 266.14K shares 10-Q · filed 2019-08-07 | |||
| 2019-03-31 | 111.13K shares 10-Q · filed 2019-05-08 | ||||
| 2018-09-30 | 45.06K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | 87.16K shares derived: sum of 2 quarters · filed 2018-11-08 | 141.54K shares 10-Q · filed 2018-11-08 | 3.42K shares derived: sum of 4 quarters · filed 2019-02-27 | |
| 2018-06-30 | 42.10K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-08 | 96.49K shares 10-Q · filed 2018-08-08 | -41.64K shares derived: sum of 3 quarters · filed 2019-02-27 | 56.14K shares derived: sum of 4 quarters · filed 2019-02-27 | |
| 2018-03-31 | 54.39K shares 10-Q · filed 2018-05-09 | -83.74K shares derived: sum of 2 quarters · filed 2019-02-27 | 14.04K shares derived: sum of 3 quarters · filed 2019-02-27 | 212.31K shares derived: sum of 4 quarters · filed 2019-02-27 | |
| 2017-12-31 | -138.13K shares derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | -40.35K shares derived: sum of 2 quarters · filed 2019-02-27 | 157.92K shares derived: sum of 3 quarters · filed 2019-02-27 | 261.34K shares 10-K · filed 2019-02-27 | 510.43K shares 10-K · filed 2018-03-07 |
| 2017-09-30 | 97.78K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | 296.05K shares derived: sum of 2 quarters · filed 2017-11-08 | 399.46K shares 10-Q · filed 2017-11-08 | ||
| 2017-06-30 | 198.27K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | 301.69K shares 10-Q · filed 2017-08-09 | |||
| 2017-03-31 | 103.42K shares 10-Q · filed 2017-05-10 | ||||
| 2016-09-30 | 58.89K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-10 | 107.14K shares 10-Q · filed 2016-11-10 | |||
| 2016-06-30 | 48.25K shares 10-Q · filed 2016-08-11 | ||||
| 2015-09-30 | 506.00 shares 10-Q · filed 2015-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |